IDEXX Laboratories Company Profile (NASDAQ:IDXX)

About IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories logoIDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:IDXX
  • CUSIP: 45168D10
  • Web:
  • Market Cap: $14.77 billion
  • Outstanding Shares: 88,123,000
Average Prices:
  • 50 Day Moving Avg: $160.98
  • 200 Day Moving Avg: $138.40
  • 52 Week Range: $85.98 - $172.00
  • Trailing P/E Ratio: 62.08
  • Foreward P/E Ratio: 48.15
  • P/E Growth: 3.17
Sales & Book Value:
  • Annual Revenue: $1.82 billion
  • Price / Sales: 8.11
  • Book Value: ($0.84) per share
  • Price / Book: -199.48
  • EBIDTA: $449.79 million
  • Net Margins: 12.51%
  • Return on Equity: -671.57%
  • Return on Assets: 15.17%
  • Debt-to-Equity Ratio: -5.48%
  • Current Ratio: 0.90%
  • Quick Ratio: 0.74%
  • Average Volume: 626,444 shs.
  • Beta: 0.48
  • Short Ratio: 4.83

Frequently Asked Questions for IDEXX Laboratories (NASDAQ:IDXX)

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings data on Friday, April, 28th. The company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.16. The business earned $462 million during the quarter, compared to the consensus estimate of $455.10 million. IDEXX Laboratories had a net margin of 12.51% and a negative return on equity of 671.57%. The company's revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.51 EPS. View IDEXX Laboratories' Earnings History.

When will IDEXX Laboratories make its next earnings announcement?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for IDEXX Laboratories.

Where is IDEXX Laboratories' stock going? Where will IDEXX Laboratories' stock price be in 2017?

5 equities research analysts have issued 1-year price targets for IDEXX Laboratories' shares. Their forecasts range from $180.00 to $185.00. On average, they anticipate IDEXX Laboratories' share price to reach $182.50 in the next year. View Analyst Ratings for IDEXX Laboratories.

What are analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

  • 1. According to Zacks Investment Research, "While over the last three months, IDEXX is trading above the broader Medical Instruments industry. The company posted an impressive first quarter with earnings and revenues growing year over year. Solid organic revenue growth buoys optimism. The stellar performance was driven by strong companion animal business. Management’s innovation-based global strategy accelerated recurring CAG Diagnostics growth. The raised 2017 EPS guidance is also encouraging. IDEXX continues to demonstrate solid growth globally with strong international expansion. On the flip side, IDEXX's high dependence on third-party distributors and intense competition continue to pose threats. Moreover foreign currency fluctuations are expected to consistently hurt IDEXX’s future growth." (5/26/2017)
  • 2. Canaccord Genuity analysts commented, "2017 will be a key year as pivotal VITALITY-ALS trial of lead skeletal muscle activator." (4/28/2017)

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a decline in short interest during the month of April. As of April 28th, there was short interest totalling 2,991,922 shares, a decline of 6.8% from the April 13th total of 3,210,026 shares. Based on an average daily trading volume, of 685,129 shares, the short-interest ratio is currently 4.4 days.

Who are some of IDEXX Laboratories' key competitors?

Who owns IDEXX Laboratories stock?

IDEXX Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.13%), BlackRock Inc. (7.30%), Fundsmith LLP (5.09%), State Street Corp (4.44%), Neuberger Berman Group LLC (2.25%) and Blair William & Co. IL (2.15%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Who sold IDEXX Laboratories stock? Who is selling IDEXX Laboratories stock?

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Neuberger Berman Group LLC, Morgan Stanley, Ameriprise Financial Inc., Blair William & Co. IL, Principal Financial Group Inc., William Blair Investment Management LLC and Bank of New York Mellon Corp. Company insiders that have sold IDEXX Laboratories stock in the last year include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Jonathan W Ayers, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Who bought IDEXX Laboratories stock? Who is buying IDEXX Laboratories stock?

IDEXX Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., State Street Corp, Renaissance Technologies LLC, Goldman Sachs Group Inc., Janus Capital Management LLC, Legal & General Group Plc and Geode Capital Management LLC. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy IDEXX Laboratories stock?

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of IDEXX Laboratories stock cost?

One share of IDEXX Laboratories stock can currently be purchased for approximately $167.56.

Analyst Ratings

Consensus Ratings for IDEXX Laboratories (NASDAQ:IDXX) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $182.50 (8.92% upside)

Analysts' Ratings History for IDEXX Laboratories (NASDAQ:IDXX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/1/2017Stifel NicolausBoost Price TargetBuy$150.00 -> $185.00LowView Rating Details
4/28/2017Canaccord GenuityReiterated RatingBuy$165.00 -> $180.00LowView Rating Details
2/3/2017Feltl & Co.DowngradeHold -> SellN/AView Rating Details
9/29/2016Bank of America CorpReiterated RatingNeutralN/AView Rating Details
8/3/2016Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
4/13/2016Credit Suisse Group AGBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
4/1/2016CL KingInitiated CoverageNeutralN/AView Rating Details
2/1/2016Piper Jaffray CompaniesReiterated RatingNeutral$73.00 -> $75.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
8/28/2015Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for IDEXX Laboratories (NASDAQ:IDXX)
Earnings by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Earnings History by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/28/2017Q1 17$0.61$0.77$455.10 million$462.00 millionViewN/AView Earnings Details
2/2/2017Q416$0.51$0.58$436.07 million$443.00 millionViewListenView Earnings Details
11/1/2016Q316$0.59$0.62$448.60 million$448.30 millionViewListenView Earnings Details
8/2/2016Q216$0.62$0.74$444.83 million$467.00 millionViewListenView Earnings Details
4/29/2016Q116$0.47$0.51$403.48 million$417.55 millionViewListenView Earnings Details
1/29/2016Q415$0.44$0.48$397.39 million$400.00 millionViewListenView Earnings Details
10/28/2015Q315$0.53$0.54$409.33 million$406.00 millionViewListenView Earnings Details
7/30/2015Q215$0.57$0.60$412.57 million$413.30 millionViewListenView Earnings Details
4/28/2015Q115$0.98$0.98$394.38 million$382.00 millionViewN/AView Earnings Details
1/30/2015Q414$0.80$0.95$373.20 million$352.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.90$1.05$371.80 million$384.00 millionViewListenView Earnings Details
7/25/2014Q214$1.06$1.10$385.20 million$390.00 millionViewN/AView Earnings Details
4/25/2014Q114$0.87$0.89$361.58 million$360.20 millionViewListenView Earnings Details
2/4/2014Q413$0.81$0.82$347.08 million$354.10 millionViewN/AView Earnings Details
10/22/2013Q313$0.83$0.86$339.70 million$338.30 millionViewN/AView Earnings Details
7/23/2013Q2 2013$0.97$0.99$356.80 million$352.60 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.83$0.81$341.06 million$332.10 millionViewN/AView Earnings Details
1/29/2013Q4 2012$0.71$0.78$325.10 million$319.50 millionViewN/AView Earnings Details
10/19/2012$0.73$0.76ViewN/AView Earnings Details
7/20/2012$0.90$0.91ViewN/AView Earnings Details
4/20/2012$0.71$0.72ViewN/AView Earnings Details
1/27/2012$0.63$0.67ViewN/AView Earnings Details
10/21/2011$0.65$0.66ViewN/AView Earnings Details
7/22/2011$0.72$0.83ViewN/AView Earnings Details
4/21/2011$0.59$0.62ViewN/AView Earnings Details
1/28/2011$0.55$0.62ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for IDEXX Laboratories (NASDAQ:IDXX)
2017 EPS Consensus Estimate: $2.83
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.59$0.61$0.60
Q2 20173$0.82$0.88$0.85
Q3 20173$0.72$0.76$0.74
Q4 20173$0.59$0.67$0.64
(Data provided by Zacks Investment Research)


Dividend History for IDEXX Laboratories (NASDAQ:IDXX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for IDEXX Laboratories (NASDAQ:IDXX)
Insider Ownership Percentage: 2.79%
Institutional Ownership Percentage: 91.42%
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017William T EndDirectorSell5,000$162.55$812,750.00View SEC Filing  
5/10/2017Jonathan W AyersChairmanSell27,000$162.69$4,392,630.00View SEC Filing  
5/5/2017Jonathan W. AyersChairmanSell26,000$160.61$4,175,860.00View SEC Filing  
5/4/2017Rebecca M HendersonDirectorSell1,700$159.95$271,915.00View SEC Filing  
3/1/2017Lawrence D KingsleyDirectorBuy1,000$146.48$146,480.00View SEC Filing  
2/22/2017Jonathan W AyersChairmanSell35,000$142.58$4,990,300.00View SEC Filing  
2/8/2017Brian P MckeonVPSell9,924$141.64$1,405,635.36View SEC Filing  
2/8/2017Daniel M JuniusDirectorSell3,000$141.75$425,250.00View SEC Filing  
2/8/2017Jonathan W. AyersChairmanSell36,250$141.63$5,134,087.50View SEC Filing  
11/29/2016Jonathan W AyersChairmanSell27,424$119.77$3,284,572.48View SEC Filing  
11/28/2016Jonathan W AyersCEOSell13,188$119.57$1,576,889.16View SEC Filing  
11/23/2016Thomas CraigDirectorSell8,500$120.06$1,020,510.00View SEC Filing  
11/9/2016Jonathan W. AyersChairmanSell40,000$107.85$4,314,000.00View SEC Filing  
11/8/2016William T EndDirectorSell5,000$109.87$549,350.00View SEC Filing  
8/25/2016Rebecca M HendersonDirectorSell9,924$110.43$1,095,907.32View SEC Filing  
8/15/2016Barry C JohnsonDirectorSell9,924$111.37$1,105,235.88View SEC Filing  
8/8/2016Michael J. Phd WilliamsInsiderSell49,560$108.94$5,399,066.40View SEC Filing  
8/5/2016William T EndDirectorSell5,000$108.50$542,500.00View SEC Filing  
8/4/2016Jonathan W. AyersChairmanSell60,000$107.69$6,461,400.00View SEC Filing  
5/5/2016William T EndDirectorSell4,924$85.87$422,823.88View SEC Filing  
2/24/2016Michael J Phd WilliamsEVPSell2,000$71.93$143,860.00View SEC Filing  
2/9/2016Thomas CraigDirectorSell2,054$69.52$142,794.08View SEC Filing  
2/8/2016Brian P. MckeonCFOSell9,054$69.65$630,611.10View SEC Filing  
11/30/2015Thomas CraigDirectorSell7,000$70.28$491,960.00View SEC Filing  
11/12/2015Rebecca M. HendersonDirectorSell2,300$68.39$157,297.00View SEC Filing  
8/31/2015Thomas CraigDirectorSell800$71.77$57,416.00View SEC Filing  
8/18/2015Michael J. Phd WilliamsEVPSell6,586$78.34$515,947.24View SEC Filing  
8/18/2015Thomas CraigDirectorSell2,900$79.41$230,289.00View SEC Filing  
8/17/2015Jonathan W AyersCEOSell14,799$78.45$1,160,981.55View SEC Filing  
5/18/2015William T EndDirectorSell3,527$134.51$474,416.77View SEC Filing  
3/10/2015William T EndDirectorSell3,500$150.89$528,115.00View SEC Filing  
3/4/2015Johnny D PowersEVPSell6,168$158.49$977,566.32View SEC Filing  
2/17/2015Brian P MckeonCFOSell5,000$156.99$784,950.00View SEC Filing  
2/12/2015Jonathan W AyersCEOSell58,245$155.45$9,054,185.25View SEC Filing  
2/5/2015Rebecca M HendersonDirectorSell2,934$156.27$458,496.18View SEC Filing  
2/4/2015Thomas CraigDirectorSell2,200$157.02$345,444.00View SEC Filing  
1/14/2015Jonathan W AyersCEOSell28,512$157.68$4,495,772.16View SEC Filing  
12/3/2014Jonathan W AyersCEOSell29,000$148.49$4,306,210.00View SEC Filing  
11/13/2014Thomas CraigDirectorSell5,000$152.45$762,250.00View SEC Filing  
11/5/2014Jonathan W AyersCEOSell29,000$143.45$4,160,050.00View SEC Filing  
11/4/2014Johnny D PowersEVPSell1,292$142.70$184,368.40View SEC Filing  
8/13/2014M Anne SzostakDirectorBuy2,000$127.03$254,060.00View SEC Filing  
2/20/2014M Anne SzostakDirectorBuy2,000$126.71$253,420.00View SEC Filing  
2/19/2014Thomas CraigDirectorSell4,800$125.42$602,016.00View SEC Filing  
2/3/2014Jonathan AyersCEOSell81,294$112.46$9,142,323.24View SEC Filing  
11/26/2013Jonathan AyersCEOSell78,178$105.29$8,231,361.62View SEC Filing  
11/22/2013Sophie VandebroekDirectorBuy1,000$107.84$107,840.00View SEC Filing  
11/13/2013Jonathan AyersCEOSell78,178$106.36$8,315,012.08View SEC Filing  
11/4/2013M Anne SzostakDirectorBuy1,000$108.24$108,240.00View SEC Filing  
11/4/2013Michael Phd WilliamsEVPSell6,020$108.19$651,303.80View SEC Filing  
10/31/2013William T EndDirectorSell2,500$108.32$270,800.00View SEC Filing  
10/25/2013Jonathan W AyersCEOSell78,178$104.36$8,158,656.08View SEC Filing  
9/13/2013Johnny PowersEVPSell13,128$96.59$1,268,033.52View SEC Filing  
9/5/2013Michael J Phd WilliamsEVPSell5,162$95.58$493,383.96View SEC Filing  
5/9/2013Ali NaquiVPSell12,961$87.00$1,127,607.00View SEC Filing  
2/4/2013Merilee RainesCFOSell175,929$94.25$16,581,308.25View SEC Filing  
11/13/2012Jonathan W AyersCEOSell15,000$89.92$1,348,800.00View SEC Filing  
9/5/2012Johnny D PowersEVPSell4,000$97.12$388,480.00View SEC Filing  
8/8/2012Merilee RainesCFOSell7,726$88.84$686,377.84View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for IDEXX Laboratories (NASDAQ:IDXX)
Latest Headlines for IDEXX Laboratories (NASDAQ:IDXX)
DateHeadline logoZacks Investment Research Downgrades IDEXX Laboratories, Inc. (IDXX) to Hold - May 26 at 1:34 PM logoIDEXX Laboratories (IDXX) Raised to Buy on Solid Prospects - Nasdaq - May 24 at 11:37 AM logoIDEXX Laboratories, Inc. (IDXX) Director William T. End Sells 5,000 Shares - May 23 at 10:25 AM logoIDEXX Laboratories, Inc. (IDXX) Raised to "Buy" at Zacks Investment Research - May 22 at 2:38 PM logoIDEXX Laboratories, Inc. (IDXX) Short Interest Update - May 21 at 7:08 AM logoIDEXX Laboratories, Inc. (IDXX) Downgraded by Zacks Investment Research - May 19 at 10:54 PM logoIDEXX Laboratories to Present at Stifel 2017 Dental and Veterinary Conference - May 17 at 5:49 PM logoWhy IDEXX Laboratories (IDXX) Could Be an Impressive Growth Stock - May 17 at 10:02 AM logoETFs with exposure to IDEXX Laboratories, Inc. : May 15, 2017 - May 15 at 5:22 PM logoIDEXX Laboratories, Inc. (IDXX) Chairman Sells $4,392,630.00 in Stock - May 11 at 7:20 PM logoIDEXX Laboratories, Inc. (IDXX) Receives Average Rating of "Hold" from Analysts - May 9 at 7:58 AM logoIDEXX Laboratories, Inc. (IDXX) Expected to Announce Earnings of $0.83 Per Share - May 9 at 12:40 AM logo$500.78 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter - May 9 at 12:40 AM logoIDEXX Laboratories, Inc. (IDXX) Chairman Sells $4,175,860.00 in Stock - May 8 at 7:17 PM logoIDEXX Laboratories, Inc. (IDXX) Director Rebecca M. Henderson Sells 1,700 Shares - May 5 at 8:37 PM logoIDEXX Laboratories, Inc. (IDXX) Expected to Post Quarterly Sales of $500.78 Million - May 5 at 12:08 PM logoETFs with exposure to IDEXX Laboratories, Inc. : May 4, 2017 - May 4 at 6:01 PM logoIDEXX Laboratories (IDXX) Earning Positive Press Coverage, AlphaOne Reports - May 4 at 11:34 AM logo$0.83 EPS Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter - May 4 at 1:37 AM logoIDEXX Labs (IDXX) Increases in Share Repurchase Program by 3M - - May 3 at 5:49 PM logoIDEXX Laboratories Announces Increase in Share Repurchase Program - May 3 at 5:49 PM logoIDEXX Laboratories, Inc. :IDXX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 - May 3 at 5:49 PM logoFavorable Press Coverage Very Likely to Impact IDEXX Laboratories (IDXX) Stock Price - May 1 at 7:32 PM logoIDEXX Laboratories, Inc. Earnings: Solid Revenue and Earnings Growth - May 1 at 6:23 PM logoIDEXX Laboratories, Inc. (IDXX) Receives "Buy" Rating from Stifel Nicolaus - May 1 at 2:18 PM logoIDEXX Laboratories, Inc. to Post Q2 2017 Earnings of $0.82 Per Share, William Blair Forecasts (IDXX) - May 1 at 8:11 AM logoIDEXX Laboratories (IDXX) Beats Q1 Earnings, Raises View - Yahoo Finance - April 29 at 6:23 PM logoIDEXX Laboratories, Inc. (IDXX) Announces Earnings Results - April 29 at 1:27 AM logoIDEXX Laboratories, Inc. (IDXX) Given "Buy" Rating at Canaccord Genuity - April 29 at 1:01 AM logoEdited Transcript of IDXX earnings conference call or presentation 28-Apr-17 12:30pm GMT - April 28 at 11:51 PM logoIDEXX Laboratories, Inc. (IDXX) Issues Quarterly Earnings Results - April 28 at 10:50 PM logoIDEXX Laboratories (IDXX) Q1 2017 Results - Earnings Call Transcript - April 28 at 6:49 PM logoIDEXX Laboratories (IDXX) Beats Q1 Earnings, Raises View - April 28 at 6:49 PM logoIDEXX Laboratories (IDXX) Receives News Sentiment Rating of 0.38 - April 28 at 2:06 PM logoIDEXX Laboratories Inc. (IDXX) Has Risen To A New High On Q1 Earnings - April 28 at 10:07 AM logoIDEXX Laboratories Announces First Quarter Results - April 28 at 10:07 AM logoIDEXX Laboratories (IDXX) Beats on Q1 Earnings & Revenues - April 28 at 10:07 AM logoIdexx tops Street 1Q forecasts - April 28 at 7:22 AM logoCommit To Purchase Idexx Laboratories At $145, Earn 2.1% Annualized Using Options - April 27 at 6:25 PM logoShould You Buy IDEXX Laboratories (IDXX) Ahead of Earnings? - April 27 at 8:38 AM logoRon Baron Comments on IDEXX Laboratories - April 26 at 7:30 PM logoIDEXX Laboratories (IDXX) Given Daily Media Impact Rating of 0.19 - April 25 at 9:06 PM logoIDEXX Laboratories, Inc. (IDXX) Rating Increased to Buy at Zacks Investment Research - April 25 at 3:40 PM logoEndo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers - April 25 at 10:46 AM logoIDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store? - April 18 at 11:06 AM logoIDEXX Laboratories (IDXX) Earning Favorable Press Coverage, Report Finds - April 16 at 1:49 PM logo$455.41 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter - April 14 at 12:38 PM logoIDEXX Laboratories, Inc. (IDXX) Given Consensus Rating of "Hold" by Analysts - April 14 at 10:10 AM logoIDEXX Laboratories (IDXX) Given News Sentiment Rating of -0.09 - April 13 at 1:54 PM logoIDEXX Laboratories, Inc. (IDXX) Expected to Announce Earnings of $0.62 Per Share - April 12 at 10:18 PM



IDEXX Laboratories (IDXX) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff